Urinary Proteomic Assessment of Ovarian Malignancy and Disease Progression

Xiangya Hospital of Central South University1 site in 1 country240 target enrollmentJanuary 1, 2025

ConditionsOvarian Cancer (OvCa)

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Ovarian Cancer (OvCa)
Sponsor: Xiangya Hospital of Central South University
Enrollment: 240
Locations: 1
Primary Endpoint: Pathological diagnosis
Status: Recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The goal of this observational study is to determine the urinary proteomic characteristics in women with and without ovarian cancer. The main questions it aims to answer are:

What is the difference in urinary protein composition between patients with ovarian cancer and those without it?
Can these differences in urinary protein composition aid in the diagnosis of ovarian cancer?
Are urinary protein markers associated with tumor burden in urine samples from patients with ovarian cancer?
Can urinary protein markers be used for disease surveillance in ovarian cancer patients?

Registry

clinicaltrials.gov

Start Date

January 1, 2025

End Date

December 31, 2027

Last Updated

last year

Study Type

Observational

Sex

Female

Investigators

Sponsor

Xiangya Hospital of Central South University

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Female patients in the gynecological ward for surgical treatment.
•Initial diagnosis of "pelvic mass" or "malignant ascites" may be considered as ovarian cancer; Or the initial diagnosis of "ovarian cyst", "hydrosalpinx", "uterine fibroids" or "uterine adenomyosis" are considered as gynecological non-malignant diseases.
•Over 18 years of age.
•Voluntary participation and signing of informed consent.

Exclusion Criteria

•Study participants with a prior history of malignant tumors.
•Study participants with prior chronic kidney disease or renal insufficiency.
•Study participants who have received or are receiving treatment for primary disease.
•Study participants whose pathological diagnosis was not clear.
•Any patient should be excluded from the study if:
•Study participants withdraw informed consent and request withdrawal.
•Study participants were unable to provide a qualified urine sample.
•There are situations in which the researcher considers it necessary to withdraw from the study.